Cemiplimab-rwlc Approved in Advanced Cutaneous Squamous Cell Carcinoma

被引：0
|
作者：
Schuyler, Devon
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：707 / 707
页数：1
相关论文
共 50 条
  • [1] Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma
    Ahmed, Saqib R.
    Petersen, Erik
    Patel, Ravi
    Migden, Michael R.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (10) : 947 - 951
  • [2] CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma
    Migden, Michael R.
    Chandra, Sunandana
    Rabinowits, Guilherme
    Chen, Chieh-, I
    Desai, Jigar
    Seluzhytsky, Alex
    Sasane, Medha
    Campanelli, Benedetta
    Chen, Zhen
    Freeman, Morganna L.
    Ibrahim, Sherrif F.
    Khushalani, Nikhil, I
    Andria, Michael
    Ruiz, Emily
    FUTURE ONCOLOGY, 2020, 16 (04) : 11 - 19
  • [3] Cemiplimab-rwlc in advanced cutaneous squamous cell carcinoma: real-world experience in a French dermatology department
    Guillaume, T.
    Puzenat, E.
    Popescu, D.
    Aubin, F.
    Nardin, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (05) : 1056 - 1058
  • [4] Demographics, prior therapies and reasons for cemiplimab treatment: Prospective cemiplimAb-rwlc survivorship and epidemiology (CASE) study in patients with advanced cutaneous squamous cell carcinoma (CSCC)
    Rabinowits, G.
    Homsi, J.
    Nikanjam, M.
    Gentry, R.
    Strasswimmer, J.
    Venna, S.
    Migden, M. R.
    Chandra, S.
    Ruiz, E.
    Zhang, H. R.
    McGinniss, J.
    Seluzhytsky, A.
    Desai, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S741 - S742
  • [5] CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting
    Rabinowits, G.
    Homsi, J.
    Park, S. J.
    Khushanlani, N.
    Panella, T.
    Ellison, D. M.
    Gentry, R. W.
    Venna, S. S.
    Strasswimmer, J.
    Zuniga, R. M.
    Chandra, S.
    Ruiz, E. S.
    Migden, M. R.
    Ibrahim, S.
    Mehta, N.
    He, X.
    Zhang, H.
    Gillis, K. A.
    Pouliot, J-F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S925 - S926
  • [6] Checkpoint inhibition in immunosuppressed or immunocompromised patients with advanced cutaneous squamous cell carcinoma (CSCC): Data from prospective CemiplimAb-rwlc Survivorship and Epidemiology (CASE) study.
    Rabinowits, Guilherme
    Park, Soo J.
    Ellison, David M.
    Worden, Francis P.
    Gentry, Rhonda W.
    Strasswimmer, John
    Venna, Suraj S.
    Migden, Michael Robert
    Chandra, Sunandana
    Ruiz, Emily S.
    Mehta, Nikita
    Zhang, Haixin Raymond
    McGinniss, Jennifer
    Desai, Jigar
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Cemiplimab in advanced cutaneous squamous cell carcinoma
    Naik, Piyu Parth
    DERMATOLOGIC THERAPY, 2021, 34 (06)
  • [8] Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma
    Hernandez-Guerrero, T.
    Doger, B.
    Moreno, V
    DRUGS OF TODAY, 2019, 55 (08) : 485 - 494
  • [9] Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma
    Villani, Alessia
    Ocampo-Garza, Sonia Sofia
    Potestio, Luca
    Fabbrocini, Gabriella
    Ocampo-Candiani, Jorge
    Ocampo-Garza, Jorge
    Scalvenzi, Massimiliano
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (01) : 21 - 29
  • [10] Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma
    Lee, Arnold
    Duggan, Sean
    Deeks, Emma D.
    DRUGS, 2020, 80 (08) : 813 - 819
12345